Abstract
One in five men over the age of 50 years will suffer an osteoporotic fracture during their lifetime, and men who sustain fractures have an increased mortality risk compared to women. Three bisphosphonates (alendronate, risedronate and zolendronic acid), denosumab, strontium ranelate and teriparatide are currently approved in Denmark for the treatment of osteoporosis in men. This review summarizes the available therapeutic options.
| Translated title of the contribution | Medical treatment of osteoporosis in men |
|---|---|
| Original language | Danish |
| Article number | V03150220 |
| Journal | Ugeskrift for Laeger |
| Volume | 177 |
| Number of pages | 7 |
| ISSN | 0041-5782 |
| Publication status | Published - 2015 |